Fujii T, Suwa A, Yosida T, Mimori T, Akizuki M
Department of Medicine, School of Medicine, Keio University, Tokyo.
Ryumachi. 1994 Jun;34(3):571-82.
Patients with rheumatoid arthritis who did not respond sufficiently to auranofin therapy were divided into three groups to be continued on auranofin monotherapy (1), to be on combination therapy of auranofin and salazosulfapyridine (2) and to be given methotrexate concomitantly with auranofin (3), and clinical responses were compared in a prospective manner. Patients on combination therapy either with salazosulfapyridine or with methotrexate demonstrated higher improvement than those on continued auranofin monotherapy. No unknown side effects associated with monotherapy of any of the three compounds were seen in any of the three groups. The study suggests usefulness of combination therapy either with methotrexate or with salazosulfapyridine for patients who failed to respond sufficiently to auranofin.
对金诺芬治疗反应欠佳的类风湿性关节炎患者被分为三组，分别继续接受金诺芬单一疗法（1组）、金诺芬与柳氮磺胺吡啶联合疗法（2组）以及金诺芬与甲氨蝶呤联合疗法（3组），并以前瞻性方式比较临床反应。接受柳氮磺胺吡啶或甲氨蝶呤联合治疗的患者比继续接受金诺芬单一疗法的患者改善更明显。三组中均未观察到与这三种化合物单一疗法相关的未知副作用。该研究表明，对于对金诺芬反应欠佳的患者，甲氨蝶呤或柳氮磺胺吡啶联合疗法是有用的。
